Valneva SE

NASDAQ:VALN

Biotechnology

Healthcare
$5.34 +0.19%

+$0.01 today

Market cap
$507.98M
Beta
1.40
P/E (TTM)
-2.9
EPS (TTM)
-$0.80
52W Low $5.06High $12.25

Volume 0.00M

Average 0.09M

VALN Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Valneva SENASDAQ: VALN

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin narrows to 15.3%

Gross margin was 15.3% in Q1 FY2026, down 37.9 pp from a year earlier. On a trailing-twelve-month basis it was 29.5%, down 17.1 pp year over year. Over 3 fiscal years it widened by 28.5 pp.

Context

  • Gross margin widened in 2 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
15.3%-9.1 pp QoQ
Last fiscal yearDec 2025
38.7%-3.2 pp YoY
LTMMar 2026
29.5%-17.1 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-37.9 pp——
1 year-3.2 pp——
3 years+28.5 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
38.7%
Year-over-year change
-3.2pp

Gross Margin vs competitors

How VALN compares with its peers on the latest reported figures

  • VALN's LTM Mar 2026 gross margin of 29.5% is the 6th highest of the 7 companies compared; the peer median is 93.9%.
  • Its year-over-year change of -17.1 pp is the lowest of 7, against a peer median of +1.0 pp.
  • Over three fiscal years its change of +28.5 pp compares with a peer median of -0.3 pp.
VALN Competitors Peer median
Gross Margin for VALN and competitors
Company Period LTM level YoY 3-year change
VIRVir Biotechnology, Inc.LTM Mar 2026275.2% +2604.6 pp+21.4 pp
INOInovio Pharmaceuticals, Inc.FY2025100.0% +0.0 pp+0.0 pp
IBRXImmunityBio, Inc.LTM Sep 202696.7% +1.9 pp-0.7 pp
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 202691.2% -8.8 pp-4.5 pp
NVAXNovavax, Inc.LTM Mar 202684.6% -2.8 pp+50.1 pp
VALNValneva SELTM Mar 202629.5% -17.1 pp+28.5 pp
MRNAModerna, Inc.LTM Sep 202628.0% +16.1 pp-16.0 pp
PCVXVaxcyte, Inc.FY2025— ——
Peer median (excluding VALN) 93.9%+1.0 pp-0.3 pp

Competitors are the stored peer set for VALN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue348.09M361.3M153.71M169.58M174.66M
Cost of Revenue187.92M324.44M100.88M98.54M107.14M
Gross Profit160.17M36.86M52.84M71.04M67.52M
Gross Margin46.0%10.2%34.4%41.9%38.7%
Research & Development173.28M104.92M59.89M74.14M85.3M
Selling, General & Admin71.25M57.58M96.55M95.11M74.68M
Operating Expenses221.56M150.31M134.92M57.71M149.15M
Depreciation & Amortization14.28M21.04M17.58M19.59M21.75M
EBITDA(38.74M)(104.73M)(57.72M)32.08M(50.47M)
EBITDA Margin-11.1%-29.0%-37.6%18.9%-28.9%
Operating Income(61.39M)(113.44M)(82.09M)13.33M(81.63M)
Operating Margin-17.6%-31.4%-53.4%7.9%-46.7%
Interest Income249K260K1.21M2.36M1.8M
Interest Expense16.96M19.05M23.33M23.98M41.9M
Other Income / Expenses(8.59M)(31.37M)(16.54M)(24.82M)(32.49M)
Income Before Tax(69.98M)(144.82M)(98.63M)(11.49M)(114.12M)
Pre-Tax Margin-20.1%-40.1%-64.2%-6.8%-65.3%
Income Tax Expense3.45M(1.54M)2.8M761K1.07M
Net Income(73.43M)(143.28M)(101.43M)(12.25M)(115.19M)
Net Margin-21.1%-39.7%-66.0%-7.2%-66.0%
EPS (Basic)(1.50)(2.48)(1.46)(0.17)(1.32)
EPS (Diluted)(1.50)(2.48)(1.46)(0.17)(1.32)
Weighted Avg Shares48.81M57.74M69.47M70.26M84.09M
Weighted Avg Shares (Diluted)48.81M57.74M69.31M70.26M84.09M

Valneva SE

NASDAQ:VALN

Intrinsic Alpha fair value

Locked

Current Price

$5.34

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.